PFZ Pfizer

TIDMPFZ

RNS Number : 9158F

Capital Group Companies Inc

16 November 2015

FORM 8.3

IRISH TAKEOVER PANEL

DISCLOSURE UNDER RULE 8.3 OF THE IRISH TAKEOVER PANEL ACT, 1997, TAKEOVER RULES, 2013

DEALINGS BY PERSONS WITH INTERESTS IN RELEVANT SECURITIES REPRESENTING 1% OR MORE

   1.       KEY INFORMATION 
 
Name of person dealing    The Capital Group 
 (Note 1)                  Companies, Inc. 
======================  ===================== 
Company dealt in             Pfizer Inc. 
======================  ===================== 
Class of relevant       US$0.05 common stock 
 security to which       (ISIN: US7170811035) 
 the dealings being 
 disclosed relate 
 (Note 2) 
======================  ===================== 
Date of dealing           13 November 2015 
======================  ===================== 
 
   2.         INTERESTS AND SHORT POSITIONS 

(a) Interests and short positions (following dealing) in the class of relevant security dealt in (Note 3)

 
                                    Long               Short 
======================  =================  =================== 
                        Number      (%)     Number       (%) 
======================  =========  ======  ===========  ====== 
(1) Relevant            143,176,913 
 securities              (2.3195%) 
======================  =================  =================== 
(2) Derivatives 
 (other than options) 
======================  =================  =================== 
(3) Options and 
 agreements to 
 purchase/sell 
======================  =================  =================== 
                        143,176,913* 
Total                    (2.3195%) 
======================  =================  =================== 
 
 

(b) Interests and short positions in relevant securities of the company, other than the class dealt in (Note 3)

 
Class of relevant                          Long                Short 
 security: 
============================  ===================  ===================== 
                              Number        (%)     Number         (%) 
============================  =========    ======  ===========    ====== 
(1) Relevant securities 
============================  ===================  ===================== 
 
  (2) Derivatives (other 
  than options) 
============================  ===================  ===================== 
 
  (3) Options and agreements 
  to purchase/sell 
============================  ===================  ===================== 
Total 
============================  ===================  ===================== 
 
 

2. DEALINGS (Note 4)

   (a)      Purchases and sales 
 
 
  Purchase/sale           Number of relevant        Price per 
                          securities                unit (Note 
                                                    5) 
===============  ===========================  ================ 
   Purchase                                      33.3500 - 
                            1,750                    USD 
===============  ===========================  ================ 
 
   (b)      Derivatives transactions (other than options transactions) 
 
Product    Nature of     Number of relevant   Price 
 name,      transaction   securities           per unit 
 e.g. CFD   (Note 6)      (Note 7)             (Note 
                                               5) 
=========  ============  ==================  ========== 
 
 
   (c)      Options transactions in respect of existing relevant securities 
   (i)       Writing, selling, purchasing or varying 
 
Product  Writing,      Number          Exercise  Type,       Expiry  Option 
 name,    selling,      of securities   price     e.g.        date    money 
 e.g.     purchasing,   to which                  American,           paid/received 
 call     varying       the option                European            per unit 
 option   etc.          relates                   etc.                (Note 
                        (Note                                         5) 
                        7) 
=======  ============  ==============  ========  ==========  ======  ============== 
 
 
   (ii)      Exercising 
 
Product name,         Number of securities      Exercise price 
 e.g. call                                       per unit (Note 
 option                                          5) 
=============  ===========================  =================== 
 
 
   (d)      Other dealings (including transactions in respect of new securities) (Note 4) 
 
Nature of            Details      Price per 
 transaction                       unit 
 (Note 8)                          (if applicable) 
                                   (Note 5) 
============  ==============  ==================== 
 
 
   3.       OTHER INFORMATION 

Agreements, arrangements or understandings relating to options or derivatives

Full details of any agreement, arrangement or understanding between the person disclosing and any other person relating to the voting rights of any relevant

securities under any option referred to on this form or relating to the voting rights or future acquisition or disposal of any relevant securities to which any

derivative referred to on this form is referenced. If none, this should be stated.

   Is a Supplemental Form 8 attached? (Note 9)                                           NO 
 
Date of disclosure            13 November 2015 
===========================  ================= 
Contact name                  Gina Martinez 
===========================  ================= 
Telephone number              +213.615.0469 
===========================  ================= 
If a connected EFM,          n/a 
 name of offeree/offeror 
 with which connected 
===========================  ================= 
If a connected EFM,          n/a 
 state nature of connection 
 (Note 10) 
===========================  ================= 
 

Y

*10,723 shares due to an off-market transfer in.

This information is provided by RNS

The company news service from the London Stock Exchange

END

ISELLFSALELRLIE

(END) Dow Jones Newswires

November 17, 2015 02:00 ET (07:00 GMT)

Pfizer (LSE:PFZ)
Gráfico Histórico do Ativo
De Jan 2025 até Fev 2025

Pfizer (LSE:PFZ)
Gráfico Histórico do Ativo
De Fev 2024 até Fev 2025